Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.50%
1,096.70
-5.48
-0.50%
—1,102.181,096.241,103.051,094.01——
SIXC
Communications
SIXC
Communications
SIXC
-0.54%
612.91
-3.33
-0.54%
—616.24616.24617.68613.11——
SIXE
Energy
SIXE
Energy
SIXE
+0.47%
1,195.26
+5.54
+0.47%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.61%
1,753.55
+27.86
+1.61%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-1.05%
636.85
-6.77
-1.05%
—643.62643.13643.17637.05——
SIXR
Staples
SIXR
Staples
SIXR
+1.44%
841.71
+11.92
+1.44%
—829.79832.32843.23832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.72%
214.94
+1.54
+0.72%
—213.40213.40216.05213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.32%
3,142.22
-41.96
-1.32%
—3,185.923,160.893,178.723,143.96——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.34%
930.23
+21.29
+2.34%
—908.94912.57932.57912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.48%
1,471.93
-7.03
-0.48%
—1,478.961,478.171,482.911,471.90——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.96%
2,382.32
-23.04
-0.96%
—2,405.362,390.342,402.532,382.93——
A1ZN34:BVMF
Astrazeneca Plc Bdr
R$161.80
0.00%
(0.00) 1D
Apr 22, 4:50:42 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1ZN34...
Mkt. cap
301.74B
Avg. vol.
409.00
Volume
0.00
52-wk high
R$190.40
52-wk low
R$123.80
Shares outstanding
1.55B
No. of employees
96K
News stories
From sources across the web
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Last report
Feb 10, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
2.12/ (2.08 est.)USD
+2.00%beat
Revenue / Estimate
15.50B/ (15.44B est.)USD
+0.38%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
13.59B
14.46B
15.19B
15.50B
Cost of goods sold
2.23B
2.55B
2.79B
3.17B
Cost of revenue
2.23B
2.55B
2.79B
3.17B
Research and development expenses
3.10B
3.51B
3.63B
3.62B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.57B
4.98B
5.20B
5.32B
Operating expense
7.56B
8.42B
8.74B
8.99B
Total operating expenses
9.79B
10.97B
11.53B
12.16B
Operating income
3.80B
3.49B
3.66B
3.35B
Other non operating income
-
-
-
-247.00M
EBT including unusual items
3.40B
3.13B
3.24B
2.63B
EBT excluding unusual items
3.52B
3.11B
3.32B
3.05B
Income tax expense
481.00M
679.00M
709.00M
300.00M
Effective tax rate
14.14%
21.71%
21.86%
11.41%
Other operating expenses
-114.00M
-72.00M
-89.00M
53.00M
Net income
2.92B
2.45B
2.53B
2.33B
Net profit margin
21.46%
16.95%
16.67%
15.00%
Earnings per share
2.49
2.17
2.38
2.12
Interest and investment income
84.00M
65.00M
85.00M
135.00M
Interest expense
-349.00M
-436.00M
-434.00M
-155.00M
Net interest expenses
-265.00M
-371.00M
-349.00M
-20.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.08B
4.88B
5.21B
4.11B
Gain or loss from assets sale
-66.00M
-21.00M
-31.00M
-37.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer